Healthpeak Properties Reports Second Quarter 2022 Results
Healthpeak Properties (NYSE: PEAK) reported Q2 2022 results with net income of $0.13 per share and Nareit FFO of $0.44 per share. The same-store cash NOI growth for the total portfolio was 3.7%, with life science and medical office segments at 4.3% and 4.5%, respectively. Healthpeak announced a $500 million share repurchase program and signed a 154,000 square foot lease with a global pharmaceutical company. The company reaffirmed its full-year guidance for diluted Nareit FFO per share at $1.70 – $1.76. A quarterly dividend of $0.30 per share will be paid on August 19, 2022.
- Nareit FFO of $0.44 per share, up from $0.28 year-over-year.
- Announced a $500 million share repurchase program.
- 154,000 square foot lease signed with a global pharmaceutical company.
- Life science and medical office Same-Store Cash NOI growth of 4.3% and 4.5%.
- Net income decreased to $0.13 per share from $0.51 year-over-year.
- CCRC segment reported a Same-Store Cash NOI decline of 2.1%.
DENVER, Aug. 2, 2022 /PRNewswire/ -- Healthpeak Properties, Inc. (NYSE: PEAK) today announced results for the second quarter ended June 30, 2022.
SECOND QUARTER 2022 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS
– Net income of
- Life Science and MOB Same-Store Portfolio Cash (Adjusted) NOI growth of
4.3% and4.5% , respectively
– South San Francisco Joint Ventures:
- Formed a new life science joint venture with a sovereign wealth fund ("SWF Partner") for the near-term redevelopment of seven buildings on Healthpeak's Pointe Grand campus in South San Francisco
- Healthpeak and its SWF Partner have also signed agreements to utilize a similar joint venture structure to develop Phases II & III of Vantage in South San Francisco
– Announced a
– Life science development:
- Signed a 154,000 square foot full-building lease with a global pharmaceutical company at Vantage Phase I in South San Francisco
- Placed in service the remaining 74,000 square feet at The Boardwalk and an additional 160,000 square feet at The Shore
$1 billion active life science developments81% pre-leased as of August 2, 2022
– Added a new
– Increased MOB full-year 2022 same-store cash NOI outlook
– Net debt to adjusted EBITDAre and liquidity were 5.1x and
– Obtained indicative lender commitments for a total of
– The Board of Directors declared a quarterly common stock cash dividend of
– Published 11th annual ESG report covering environmental, social and governance initiatives and progress
SECOND QUARTER COMPARISON
Three Months Ended | Three Months Ended | |||||||
(in thousands, except per share amounts) | Amount | Per Share | Amount | Per Share | ||||
Net income, diluted | $ 68,057 | $ 0.13 | $ 277,533 | $ 0.51 | ||||
Nareit FFO, diluted | 238,506 | 0.44 | 149,671 | 0.28 | ||||
FFO as Adjusted, diluted | 238,829 | 0.44 | 219,386 | 0.40 | ||||
AFFO, diluted | 197,244 | 190,579 | ||||||
Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "June 30, 2022 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.
SAME-STORE ("SS") OPERATING SUMMARY
The table below outlines the year-over-year three-month SS Cash (Adjusted) NOI growth on an actual and pro forma basis. The Pro Forma table reflects the results excluding government grants under the CARES Act for our CCRC portfolio.
Actual | ||||||
Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth | ||||||
Three Month | Year-To-Date | |||||
SS Growth % | % of SS | SS Growth % | % of SS | |||
Life science | 4.3 % | 49.4 % | 4.8 % | 48.3 % | ||
Medical office | 4.5 % | 40.0 % | 4.1 % | 39.6 % | ||
CCRC | (2.1 %) | 10.6 % | 6.2 % | 12.1 % | ||
Total Portfolio | 3.7 % | 100.0 % | 4.7 % | 100.0 % | ||
Pro Forma (excluding CARES) | ||||||
Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth | ||||||
Three Month | Year-To-Date | |||||
SS Growth % | % of SS | SS Growth % | % of SS | |||
Life science | 4.3 % | 49.4 % | 4.8 % | 49.0 % | ||
Medical office | 4.5 % | 40.0 % | 4.1 % | 40.2 % | ||
CCRC | (2.6 %) | 10.6 % | (4.3 %) | 10.8 % | ||
Total Portfolio | 3.6 % | 100.0 % | 3.5 % | 100.0 % | ||
SOUTH SAN FRANCISCO JOINT VENTURES
POINTE GRAND REDEVELOPMENT
In August 2022, Healthpeak and its SWF Partner entered into a new
The JV intends to capitalize on Pointe Grand's irreplaceable location and strong tenant demand by redeveloping the buildings upon the near-term expirations of existing leases. The redevelopment will create differentiated product in an A+ location offering tenants speed to market in high-quality, purpose-built lab space at a lower occupancy cost compared to new development. The smaller buildings also allow the JV to capture the significant demand from a deep pool of tenants seeking 20,000 to 50,000 square feet.
The JV expects to fund an additional investment of approximately
The JV generated cash proceeds to Healthpeak of
VANTAGE PHASES II & III DEVELOPMENT
Healthpeak and its SWF Partner have also signed agreements to utilize a similar joint venture structure to develop Phases II and III of Vantage, a Class A development campus that is directly adjacent to Pointe Grand in South San Francisco and currently wholly-owned by Healthpeak. The purchase price for the Vantage Phase II & III joint venture is subject to final entitlements/density, and closing is subject to certain closing conditions, which we expect will be satisfied in the first half of 2023.
SHARE REPURCHASE AUTHORIZATION
In August 2022, Healthpeak's Board of Directors approved a
DEVELOPMENT UPDATES
VANTAGE PHASE I
In July 2022, Healthpeak signed a 154,000 square foot lease with a global pharmaceutical company at its Vantage Phase I development in South San Francisco, bringing the property to
Strategically located on the corner of Forbes Boulevard and at the doorstep of Genentech's headquarters, the purpose-built lab campus will feature state-of-the-art design, an amenity center, flexible and efficient floor plates, and building systems accommodating a broad range of life science uses.
MOB DEVELOPMENT PROGRAM WITH HCA
In July 2022, Healthpeak added a new
Since 2019, Healthpeak's development program with HCA has delivered 9 MOBs totaling 780,000 square feet, with total development costs of approximately
THE BOARDWALK
During the second quarter, Healthpeak placed in service the remaining 74,000 square feet, representing
THE SHORE AT SIERRA POINT
During the second quarter, Healthpeak placed in service 160,000 square feet, representing
ACQUISITIONS
NORTHWEST MEDICAL PLAZA
In May 2022, Healthpeak closed on a 68,000 square foot on-campus medical office building for
DISPOSITIONS
During the second quarter, Healthpeak closed on the sale of three non-core MOB assets, generating proceeds of
BALANCE SHEET
Net debt to adjusted EBITDAre and liquidity were 5.1x and
Healthpeak has obtained indicative lender commitments for proposed new senior unsecured delayed draw term loans (the "Term Loan Facilities") in an aggregate principal amount of up to
ESG
In July 2022, Healthpeak published its 11th annual ESG Report, highlighting our environmental, social, and governance (ESG) initiatives over the last decade, as well as our 2021 performance.
Healthpeak was recently named an ENERGY STAR Partner of the Year for the second time and received several workplace recognitions, including being certified a Great Place to Work for the third consecutive year, Great Place to Work in Orange County by the Orange County Business Journal for the second time, and Top Workplaces by The Tennessean for the first time.
To learn more about Healthpeak's ESG program and view our 2021 ESG Report, please visit www.healthpeak.com/esg.
DIVIDEND
On July 28, 2022, Healthpeak announced that its Board declared a quarterly common stock cash dividend of
2022 GUIDANCE
We are reaffirming the following guidance ranges for full year 2022:
- Diluted Nareit FFO per share of
$1.70 –$1.76 - Diluted FFO as Adjusted per share of
$1.68 –$1.74
We are updating the following guidance ranges for full year 2022:
- Diluted earnings per common share from
$0.58 –$0.64 to$0.97 –$1.03 - Total Portfolio Same-Store Cash (Adjusted) NOI growth Guidance from
3.25% –4.75% to3.50% –5.00%
These estimates do not reflect the potential impact from unannounced future transactions. These estimates are based on our view of existing market conditions, transaction timing and other assumptions for the year ending December 31, 2022. For additional details and assumptions underlying this guidance, please see page 38 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.
COMPANY INFORMATION
Healthpeak has scheduled a conference call and webcast for Wednesday, August 3, 2022, at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time) to review its financial and operating results for the quarter ended June 30, 2022. The conference call is accessible by dialing (888) 317-6003 (U.S.) or (412) 317-6061 (international). The conference ID number is 10168631. You may also access the conference call via webcast in the Investor Relations section of our website at http://ir.healthpeak.com. An archive of the webcast will be available on Healthpeak's website through August 3, 2023, and a telephonic replay can be accessed through August 10, 2022, by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (international) and entering conference ID number 6376533. Our Supplemental Report for the current period is also available, with this earnings release, in the Investor Relations section of our website.
ABOUT HEALTHPEAK
Healthpeak Properties, Inc. is a fully integrated real estate investment trust ("REIT") and S&P 500 company. Healthpeak owns and develops high-quality real estate in the three private-pay healthcare asset classes of Life Science, Medical Office and CCRC. At Healthpeak, we pair our deep understanding of the healthcare real estate market with a strong vision for long-term growth. For more information regarding Healthpeak, visit www.healthpeak.com.
FORWARD-LOOKING STATEMENTS
Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, capital recycling plans, financing activities, or other transactions discussed in this release; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2022 Guidance." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: the Covid pandemic and health and safety measures intended to reduce its spread, the availability, effectiveness and public usage and acceptance of vaccines, and how quickly and to what extent normal economic and operating conditions can resume within the markets in which we operate; the ability of our existing and future tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and manage their expenses in order to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations; increased competition, operating costs and market changes affecting our tenants, operators and borrowers; the financial condition of our tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested in multiple industries and exposes us to the risks inherent in illiquid investments; our ability to identify and secure replacement tenants and operators and the potential renovation costs and regulatory approvals associated therewith; our property development, redevelopment and tenant improvement activity risks, including project abandonments, project delays and lower profits than expected; changes within the life science industry; high levels of regulation, funding requirements, expense and uncertainty faced by our life science tenants; the ability of the hospitals on whose campuses our MOBs are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to maintain or expand our hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our RIDEA lease structures; economic and other conditions that negatively affect geographic areas from which we recognize a greater percentage of our revenue; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners' financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose on collateral securing our real estate-related loans; our ability to make material acquisitions and successfully integrate them; the potential impact on us and our tenants, operators and borrowers from litigation matters, including rising liability and insurance costs; an increase in our borrowing costs, including due to higher interest rates; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, volatility or uncertainty in the capital markets, and other factors; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; changes in global, national and local economic and other conditions; laws or regulations prohibiting eviction of our tenants; the failure of our tenants, operators and borrowers to comply with federal, state and local laws and regulations, including resident health and safety requirements, as well as licensure, certification and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety and other regulations; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administration decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; environmental compliance costs and liabilities associated with our real estate investments; our ability to maintain our qualification as a REIT; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; the loss or limited availability of our key personnel; our reliance on information technology systems and the potential impact of system failures, disruptions or breaches; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.
CONTACT
Andrew Johns, CFA
Senior Vice President – Investor Relations
720-428-5400
Healthpeak Properties, Inc. | ||||
Consolidated Balance Sheets | ||||
In thousands, except share and per share data | ||||
June 30, 2022 | December 31, 2021 | |||
Assets | ||||
Real estate: | ||||
Buildings and improvements | $ 12,590,403 | $ 12,025,271 | ||
Development costs and construction in progress | 675,713 | 877,423 | ||
Land | 2,705,260 | 2,603,964 | ||
Accumulated depreciation and amortization | (3,097,748) | (2,839,229) | ||
Net real estate | 12,873,628 | 12,667,429 | ||
Net investment in direct financing leases | — | 44,706 | ||
Loans receivable, net of reserves of | 413,962 | 415,811 | ||
Investments in and advances to unconsolidated joint ventures | 402,154 | 403,634 | ||
Accounts receivable, net of allowance of | 47,340 | 48,691 | ||
Cash and cash equivalents | 73,013 | 158,287 | ||
Restricted cash | 54,815 | 53,454 | ||
Intangible assets, net | 470,865 | 519,760 | ||
Assets held for sale and discontinued operations, net | 66,647 | 37,190 | ||
Right-of-use asset, net | 233,391 | 233,942 | ||
Other assets, net | 682,388 | 674,615 | ||
Total assets | $ 15,318,203 | $ 15,257,519 | ||
Liabilities and Equity | ||||
Bank line of credit and commercial paper | $ 1,448,569 | $ 1,165,975 | ||
Senior unsecured notes | 4,655,852 | 4,651,933 | ||
Mortgage debt | 349,329 | 352,081 | ||
Intangible liabilities, net | 169,622 | 177,232 | ||
Liabilities related to assets held for sale and discontinued operations, net | 15,869 | 15,056 | ||
Lease liability | 201,124 | 204,547 | ||
Accounts payable, accrued liabilities, and other liabilities | 706,819 | 755,384 | ||
Deferred revenue | 814,754 | 789,207 | ||
Total liabilities | 8,361,938 | 8,111,415 | ||
Commitments and contingencies | ||||
Redeemable noncontrolling interests | 115,877 | 87,344 | ||
Common stock, | 539,580 | 539,097 | ||
Additional paid-in capital | 10,073,712 | 10,100,294 | ||
Cumulative dividends in excess of earnings | (4,306,762) | (4,120,774) | ||
Accumulated other comprehensive income (loss) | (1,318) | (3,147) | ||
Total stockholders' equity | 6,305,212 | 6,515,470 | ||
Joint venture partners | 334,120 | 342,234 | ||
Non-managing member unitholders | 201,056 | 201,056 | ||
Total noncontrolling interests | 535,176 | 543,290 | ||
Total equity | 6,840,388 | 7,058,760 | ||
Total liabilities and equity | $ 15,318,203 | $ 15,257,519 | ||
Healthpeak Properties, Inc. | ||||||||
Consolidated Statements of Operations | ||||||||
In thousands, except per share data | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2022 | 2021 | 2022 | 2021 | |||||
Revenues: | ||||||||
Rental and related revenues | $ 387,079 | $ 340,642 | $ 757,229 | $ 668,614 | ||||
Resident fees and services | 125,360 | 117,308 | 246,920 | 233,436 | ||||
Income from direct financing leases | — | 2,180 | 1,168 | 4,343 | ||||
Interest income | 5,493 | 16,108 | 10,987 | 25,121 | ||||
Total revenues | 517,932 | 476,238 | 1,016,304 | 931,514 | ||||
Costs and expenses: | ||||||||
Interest expense | 41,867 | 38,681 | 79,453 | 85,524 | ||||
Depreciation and amortization | 180,489 | 171,459 | 358,222 | 328,997 | ||||
Operating | 215,044 | 190,132 | 422,291 | 371,893 | ||||
General and administrative | 24,781 | 24,088 | 48,612 | 48,990 | ||||
Transaction costs | 612 | 619 | 908 | 1,417 | ||||
Impairments and loan loss reserves (recoveries), net | 139 | 931 | 271 | 4,173 | ||||
Total costs and expenses | 462,932 | 425,910 | 909,757 | 840,994 | ||||
Other income (expense): | ||||||||
Gain (loss) on sales of real estate, net | 10,340 | 175,238 | 14,196 | 175,238 | ||||
Gain (loss) on debt extinguishments | — | (60,865) | — | (225,157) | ||||
Other income (expense), net | 2,861 | 1,734 | 21,177 | 3,934 | ||||
Total other income (expense), net | 13,201 | 116,107 | 35,373 | (45,985) | ||||
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 68,201 | 166,435 | 141,920 | 44,535 | ||||
Income tax benefit (expense) | 718 | 763 | (59) | 755 | ||||
Equity income (loss) from unconsolidated joint ventures | 382 | 867 | 2,466 | 2,190 | ||||
Income (loss) from continuing operations | 69,301 | 168,065 | 144,327 | 47,480 | ||||
Income (loss) from discontinued operations | 2,992 | 113,960 | 3,309 | 383,968 | ||||
Net income (loss) | 72,293 | 282,025 | 147,636 | 431,448 | ||||
Noncontrolling interests' share in continuing operations | (3,955) | (3,535) | (7,685) | (6,841) | ||||
Noncontrolling interests' share in discontinued operations | — | (2,210) | — | (2,539) | ||||
Net income (loss) attributable to Healthpeak Properties, Inc. | 68,338 | 276,280 | 139,951 | 422,068 | ||||
Participating securities' share in earnings | (281) | (287) | (2,258) | (2,732) | ||||
Net income (loss) applicable to common shares | $ 68,057 | $ 275,993 | $ 137,693 | $ 419,336 | ||||
Basic earnings (loss) per common share: | ||||||||
Continuing operations | $ 0.12 | $ 0.30 | $ 0.25 | $ 0.07 | ||||
Discontinued operations | 0.01 | 0.21 | 0.01 | 0.71 | ||||
Net income (loss) applicable to common shares | $ 0.13 | $ 0.51 | $ 0.26 | $ 0.78 | ||||
Diluted earnings (loss) per common share: | ||||||||
Continuing operations | $ 0.12 | $ 0.30 | $ 0.25 | $ 0.07 | ||||
Discontinued operations | 0.01 | 0.21 | 0.01 | 0.71 | ||||
Net income (loss) applicable to common shares | $ 0.13 | $ 0.51 | $ 0.26 | $ 0.78 | ||||
Weighted average shares outstanding: | ||||||||
Basic | 539,558 | 538,929 | 539,456 | 538,805 | ||||
Diluted | 539,815 | 544,694 | 539,701 | 539,081 | ||||
Healthpeak Properties, Inc. | |||||||||
Funds From Operations | |||||||||
In thousands, except per share data | |||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||
2022 | 2021 | 2022 | 2021 | ||||||
Net income (loss) applicable to common shares | $ 68,057 | $ 275,993 | $ 137,693 | $ 419,336 | |||||
Real estate related depreciation and amortization | 180,489 | 171,459 | 358,222 | 328,997 | |||||
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures | 5,210 | 2,869 | 10,345 | 7,322 | |||||
Noncontrolling interests' share of real estate related depreciation and amortization | (4,844) | (4,923) | (9,685) | (9,809) | |||||
Loss (gain) on sales of depreciable real estate, net(1) | (12,903) | (297,476) | (16,688) | (557,138) | |||||
Healthpeak's share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures | 129 | (5,866) | (150) | (5,866) | |||||
Noncontrolling interests' share of gain (loss) on sales of depreciable real estate, net | — | 2,179 | 12 | 2,179 | |||||
Loss (gain) upon change of control, net | — | — | — | (1,042) | |||||
Taxes associated with real estate dispositions | 16 | 1,693 | (166) | 2,183 | |||||
Impairments (recoveries) of depreciable real estate, net | — | 3,743 | — | 3,743 | |||||
Nareit FFO applicable to common shares | 236,154 | 149,671 | 479,583 | 189,905 | |||||
Distributions on dilutive convertible units and other | 2,352 | — | 4,704 | — | |||||
Diluted Nareit FFO applicable to common shares | $ 238,506 | $ 149,671 | $ 484,287 | $ 189,905 | |||||
Diluted Nareit FFO per common share | $ 0.44 | $ 0.28 | $ 0.89 | $ 0.35 | |||||
Weighted average shares outstanding - diluted Nareit FFO | 547,132 | 539,193 | 547,018 | 539,081 | |||||
Impact of adjustments to Nareit FFO: | |||||||||
Transaction-related items | $ 596 | $ 1,265 | $ 893 | $ 5,379 | |||||
Other impairments (recoveries) and other losses (gains), net(2) | 139 | 1,845 | (8,770) | 5,087 | |||||
Restructuring and severance related charges | — | — | — | 2,463 | |||||
Loss (gain) on debt extinguishments | — | 60,865 | — | 225,157 | |||||
Casualty-related charges (recoveries), net | (411) | 3,596 | (411) | 4,644 | |||||
Total adjustments | 324 | 67,571 | (8,288) | 242,730 | |||||
FFO as Adjusted applicable to common shares | 236,478 | 217,242 | 471,295 | 432,635 | |||||
Distributions on dilutive convertible units and other | 2,351 | 2,144 | 4,719 | 4,067 | |||||
Diluted FFO as Adjusted applicable to common shares | $ 238,829 | $ 219,386 | $ 476,014 | $ 436,702 | |||||
Diluted FFO as Adjusted per common share | $ 0.44 | $ 0.40 | $ 0.87 | $ 0.80 | |||||
Weighted average shares outstanding - diluted FFO as Adjusted | 547,132 | 546,519 | 547,018 | 546,407 | |||||
_______________________________________ | |
(1) | This amount can be reconciled by combining the balances from the corresponding line of the Consolidated Statements of Operations of this Earnings Release and the detailed financial information in the Discontinued Operations Reconciliation section included in the corresponding Discussion and Reconciliation of Non-GAAP Financial Measures, which is available in the Investor Relations section of our website at http://ir.healthpeak.com/. |
(2) | The six months ended June 30, 2022 includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) a |
Healthpeak Properties, Inc. | ||||||||
Adjusted Funds From Operations | ||||||||
In thousands | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2022 | 2021 | 2022 | 2021 | |||||
FFO as Adjusted applicable to common shares | $ 432,635 | |||||||
Amortization of stock-based compensation | 5,300 | 5,095 | 10,021 | 9,459 | ||||
Amortization of deferred financing costs | 2,689 | 2,121 | 5,377 | 4,334 | ||||
Straight-line rents | (12,713) | (6,201) | (23,872) | (15,336) | ||||
AFFO capital expenditures | (27,906) | (22,422) | (50,745) | (43,132) | ||||
Deferred income taxes | (1,188) | (2,771) | (927) | (4,493) | ||||
Other AFFO adjustments | (7,065) | (4,026) | (13,524) | (9,628) | ||||
AFFO applicable to common shares | 195,595 | 189,038 | 397,625 | 373,839 | ||||
Distributions on dilutive convertible units and other | 1,649 | 1,541 | 3,296 | 2,862 | ||||
Diluted AFFO applicable to common shares | $ 376,701 | |||||||
Weighted average shares outstanding - diluted AFFO | 545,307 | 544,694 | 545,193 | 544,582 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/healthpeak-properties-reports-second-quarter-2022-results-301598369.html
SOURCE Healthpeak Properties, Inc.
FAQ
What were Healthpeak's Q2 2022 financial results?
How much was the share repurchase program announced by Healthpeak?
What is the Same-Store Cash NOI growth for Healthpeak's Life Science segment?
What dividend will Healthpeak pay in August 2022?
What is Healthpeak's guidance for diluted Nareit FFO in 2022?
